Bal Pharma is currently trading at Rs. 71.00, up by 3.40 points or 5.03% from its previous closing of Rs. 67.60 on the BSE.
The scrip opened at Rs. 67.50 and has touched a high and low of Rs. 70.00 and Rs. 66.50 respectively. So far 2,273 shares were traded on the counter.
The BSE group 'B ' stock of face value Rs. 10 has touched a 52 week high of Rs. 103.80 on 05-Nov-2014 and a 52 week low of Rs. 50.00 on 27-Mar-2015.
Last one week high and low of the scrip stood at Rs. 71.00 and Rs. 64.55 respectively. The current market cap of the company is Rs. 91.00 crore.
The promoters holding in the company stood at 48.83% while Institutions and Non-Institutions held 0.02% and 51.15% respectively.
Bal Pharma has launched its maiden over the counter (OTC) product ‘Eye Spa’ in Bangalore market. This is first among the series of OTC products that the company has lined up for launching in the market through its subsidiary i.e Lifezeh Healthcare. The company plans to roll out its products in other south Indian markets shortly, before their PAN India launch.
‘Eye Spa’ is a unique product which soothes and rejuvenates the tired eyes, due to their continuous exposure to dust, TV /computer screen , air conditioning and other modern lifestyle disorders.
Bal Pharma is in the business interest in area of manufacturing API, finished formulations, ayurvedic and research and development. It is one of the leading Indian pharmaceutical companies that focuses on prescription drugs, generic, OTC products, intravenous infusion and bulk actives.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1665.25 |
| Dr. Reddys Lab | 1220.75 |
| Cipla | 1232.90 |
| Zydus Lifesciences | 928.85 |
| Lupin | 2311.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: